Home » Healthcare » Gestational Diabetes Market

Gestational Diabetes Market By Treatment Segment (Insulin Therapy (Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin), Oral Medications (Metformin, Sulfonylureas)); By Diagnosis Segment (Glucose Challenge Test (GCT), Oral Glucose Tolerance Test (OGTT)); By End-user Segment (Hospitals, Clinics, Home Care Settings, Diagnostic Centers, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Name: Gestational Diabetes Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2025-07-31
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: Gestational Diabetes Market

Summary
Table Of Content

Market Overview:

The Global Gestational Diabetes Market size was valued at USD 6,890.00 million in 2018 to USD 9,471.43 million in 2024 and is anticipated to reach USD 18,814.79 million by 2032, at a CAGR of 9.01% during the forecast period.

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Gestational Diabetes Market Size 2024	USD 9,471.43 million
Gestational Diabetes Market, CAGR	9.01%
Gestational Diabetes Market Size 2032	USD 18,814.79 million

The market is driven by the growing prevalence of gestational diabetes, influenced by rising maternal age, obesity rates, and sedentary lifestyles. Increasing awareness of prenatal health and government-led screening programs are improving early diagnosis and management. Healthcare providers are adopting advanced diagnostic tools and treatment protocols, including insulin therapies and oral hypoglycemics, to ensure maternal and fetal safety. Technological advancements in continuous glucose monitoring systems also play a critical role in enhancing patient outcomes and compliance, further fueling market growth across both developed and developing regions.

Geographically, North America leads the gestational diabetes market due to its advanced healthcare infrastructure, high diagnosis rate, and awareness programs. Europe follows closely with significant institutional support for maternal health. Meanwhile, the Asia Pacific region is emerging rapidly, driven by a large population base, growing urbanization, and a rising number of high-risk pregnancies. Countries like China and India are witnessing increased demand for screening and treatment solutions due to their expanding middle-class population and government healthcare initiatives. Latin America and the Middle East & Africa also show potential as healthcare access continues to improve.

Market Insights:

The Global Gestational Diabetes Market was valued at USD 6,890.00 million in 2018, reached USD 9,471.43 million in 2024, and is projected to reach USD 18,814.79 million by 2032, growing at a CAGR of 9.01%.
Rising obesity rates, maternal age, and sedentary lifestyles are key drivers increasing gestational diabetes prevalence worldwide.
Government mandates and healthcare initiatives promoting routine prenatal screening support early detection and timely treatment.
Limited awareness in rural areas and low-resource settings continues to restrict diagnosis and care access.
Technological advancements such as continuous glucose monitoring and digital health platforms enhance treatment compliance and monitoring.
North America leads the market due to strong healthcare infrastructure and policy support, while Asia Pacific emerges as a high-growth region driven by increasing population and urbanization.
Variability in diagnostic protocols and healthcare infrastructure across regions poses a restraint on consistent market growth.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Drivers:

Rising Global Incidence of Gestational Diabetes Due to Lifestyle and Demographic Changes:

The increasing prevalence of gestational diabetes is directly linked to sedentary lifestyles, unhealthy diets, and the growing obesity burden. Women entering pregnancy at a later age experience higher risks of glucose intolerance, raising gestational diabetes diagnoses. Urbanization has contributed to reduced physical activity and poor nutritional habits, both recognized as major risk factors. The Global Gestational Diabetes Market expands due to the medical community’s emphasis on identifying and managing glucose abnormalities early in pregnancy. Demand for maternal-fetal monitoring and personalized care plans grows as awareness rises. The healthcare industry prioritizes early intervention strategies to reduce maternal and neonatal complications. Governments also implement population-based screening initiatives to address growing caseloads. These factors collectively drive the market’s growth trajectory.

For instance, Novo Nordisk has implemented educational and clinical programs in collaboration with healthcare providers in over 70 countries, which have resulted in a measurable increase in early gestational diabetes screening coverage, helping identify more at-risk pregnant women compared to standard protocols.

Strong Support from Government and Public Health Organizations to Promote Screening Programs

Public health policies increasingly mandate routine gestational diabetes screening during pregnancy. National guidelines in countries such as the U.S., Canada, and China recommend early and repeated glucose tolerance tests. Governments allocate funding to expand maternal health infrastructure and training for healthcare workers. These efforts ensure timely diagnosis, reducing the risks of pregnancy complications and long-term health issues in mothers and infants. It strengthens healthcare systems’ ability to track, intervene, and manage gestational diabetes efficiently. The Global Gestational Diabetes Market benefits from this systemic prioritization of maternal health. Incentives for public-private collaboration foster access to affordable testing tools. Enhanced integration of diagnostic services into primary care accelerates demand and expands the market footprint.

For instance, Roche Diagnostics partnered with the Indian government’s GDM screening initiative, providing their Accu-Chek diagnostic systems, which facilitated over 1.2 million glucose tests in public health centers within one year, significantly increasing detection rates of gestational diabetes in underserved regions.

Increasing Adoption of Technological Innovations in Diagnosis and Monitoring:

Technological advancements play a crucial role in expanding early detection and disease management capabilities. Healthcare providers adopt digital tools like continuous glucose monitoring (CGM) and connected glucometers for accurate, real-time tracking. These devices support proactive care, minimizing risks through data-driven interventions. Smartphone-linked platforms allow pregnant women to manage their condition and communicate with healthcare professionals effectively. The Global Gestational Diabetes Market gains momentum from the availability of user-friendly diagnostic devices. Innovations in non-invasive and rapid testing reduce patient discomfort and improve compliance. Start-ups and established med-tech firms invest heavily in research to improve testing accuracy and turnaround time. These innovations position technology as a cornerstone of gestational diabetes care.

Expanding Healthcare Access in Developing Economies Boosting Diagnosis Rates:

Healthcare infrastructure continues to improve in middle-income countries across Asia, Africa, and Latin America. With more women receiving prenatal care, diagnosis rates of gestational diabetes increase significantly. Government-funded health programs and insurance expansions drive maternal care access in underserved regions. The Global Gestational Diabetes Market sees significant growth in these areas due to greater diagnostic availability. Community-based awareness campaigns help overcome cultural barriers and encourage pregnant women to seek timely screening. Multinational companies target these regions by introducing affordable diagnostics and treatment solutions. Partnerships with local providers strengthen supply chains and market presence. With rising awareness and infrastructure upgrades, emerging markets are becoming key growth drivers.

Market Trends:

Integration of Digital Health Platforms for Gestational Diabetes Management:

Digital health solutions are becoming integral to managing gestational diabetes with increased precision and convenience. Mobile applications now help track blood glucose, medication schedules, nutrition intake, and physical activity. Many of these platforms integrate with wearable glucose monitors, creating a comprehensive management ecosystem. Telehealth services support continuous engagement between patients and healthcare providers. The Global Gestational Diabetes Market benefits from such platforms that empower patient self-management. AI-enabled platforms offer personalized alerts and recommendations to improve compliance. Digital tools improve health outcomes by enabling early interventions. They also reduce healthcare costs by minimizing emergency visits. The trend highlights the shift toward decentralized and patient-centric care models.

For instance, Welldoc’s BlueStar® app, cleared by the FDA, has been shown in clinical studies to reduce mean fasting blood glucose by 23 mg/dl in gestational diabetes users over 12 weeks, while maintaining an 87% weekly engagement rate among patients.

Growing Demand for Plant-Based and Low Glycemic Index Diet Products:

Dietary control is a critical component of gestational diabetes management, prompting a surge in demand for specialized nutritional products. Pregnant women increasingly choose plant-based, high-fiber, and low-glycemic foods to stabilize blood sugar levels. Food companies respond by offering tailored products such as low-carb meal kits and sugar-free snacks. The Global Gestational Diabetes Market aligns with this dietary trend through partnerships with food and nutrition companies. Hospitals and clinics also promote dietary education programs, reinforcing long-term healthy eating habits. Nutrition start-ups explore new formulations for diabetic-friendly supplements and drinks. Increasing awareness of food as medicine drives consumer preference for preventive nutrition. This trend supports both clinical outcomes and commercial growth.

For instance, Abbott’s Glucerna® line, clinically formulated for blood sugar management, is recommended in over 100 hospital-based gestational diabetes nutrition programs in the U.S., and clinical evaluations have demonstrated improved 2-hour postprandial glucose profiles in pregnant women regularly using these products in meal plans.

Collaborations Between Diagnostic Companies and Pharmaceutical Firms:

Strategic alliances between diagnostics and pharmaceutical companies are shaping innovation in the gestational diabetes space. Firms combine diagnostic capabilities with therapeutics to create end-to-end care models. Companion diagnostics help identify patients who would benefit from specific drug regimens. The Global Gestational Diabetes Market is seeing integrated product development pipelines emerge from such collaborations. These efforts accelerate the commercialization of new insulin formulations and oral antidiabetic drugs. Partnerships also support co-branded awareness campaigns and bundled care offerings. Regulatory pathways become more streamlined when diagnostics and treatments evolve together. The trend signals a move toward value-based healthcare solutions.

Focus on Early Biomarker Research for Predictive Diagnosis:

Researchers are investing in the identification of early biomarkers that could predict gestational diabetes before symptoms emerge. Studies explore the genetic, metabolic, and hormonal markers detectable during the first trimester. Early prediction enables more personalized interventions and better maternal outcomes. The Global Gestational Diabetes Market shows growing interest in this area due to its transformative clinical potential. Pharmaceutical companies are funding academic collaborations to validate new testing methods. Biomarker-based diagnostics could reduce dependence on glucose tolerance tests. Such predictive approaches align with the broader trend of precision medicine. This trend aims to improve disease forecasting and reduce complications through pre-emptive action.

Market Challenges Analysis:

Limited Awareness and Delayed Diagnosis in Low-Income and Rural Areas:

Despite rising global incidence, many women in underserved regions remain undiagnosed due to lack of awareness and healthcare access. Rural populations often have limited access to trained professionals and diagnostic tools. Cultural taboos and misinformation about pregnancy-related disorders further hinder early detection. In such settings, gestational diabetes is frequently detected late, increasing the risk of complications. The Global Gestational Diabetes Market must overcome these barriers through education and outreach programs. Efforts to localize screening guidelines and deploy mobile health units are critical. However, funding and infrastructure constraints continue to slow progress. Without targeted intervention, diagnosis gaps will persist in emerging economies.

Complexity in Treatment Adherence and Monitoring Compliance:

Effective management of gestational diabetes depends on strict dietary control, medication compliance, and regular glucose monitoring. Many patients struggle to adhere to treatment due to lifestyle constraints or lack of support. Insulin administration and frequent glucose checks can be challenging for first-time mothers. Even in developed countries, disparities in digital literacy and healthcare access affect compliance. It leads to inconsistent outcomes and raises long-term health risks. The Global Gestational Diabetes Market must address behavioral barriers by promoting personalized care plans. Healthcare providers face difficulties scaling individualized counselling in resource-constrained settings. This challenge limits the full effectiveness of available treatment solutions.

Market Opportunities:

Expanding Use of AI and Remote Monitoring Tools in Maternal Healthcare:

Artificial intelligence and remote patient monitoring technologies are creating new possibilities for early detection and personalized management. Predictive analytics can flag high-risk pregnancies using historical and real-time data. AI-powered tools assist healthcare professionals in making timely decisions. The Global Gestational Diabetes Market gains momentum from these innovations by improving outcomes and lowering care costs. Integration of remote devices supports regular monitoring without frequent clinic visits. These technologies also facilitate broader population screening in remote locations. Start-ups focusing on maternal health tech can capture untapped market segments through scalable AI solutions.

Rising Demand for Affordable Point-of-Care Testing Solutions:

Low-cost, rapid diagnostic tools are critical in expanding access to early gestational diabetes detection. Manufacturers are developing portable glucose testing kits tailored for use in community clinics and home settings. It helps reduce diagnostic delays in low-resource environments. The Global Gestational Diabetes Market is seeing increased investment in such solutions to reach underdiagnosed populations. Distribution through public health programs expands reach while ensuring cost-effectiveness. This opportunity enables companies to address healthcare equity and scale impact in emerging regions.

Market Segmentation Analysis:

By Treatment

The Global Gestational Diabetes Market by treatment is led by insulin therapy, which remains the standard for managing moderate to severe cases. Rapid-acting and short-acting insulin types offer precise glycemic control around meals, while intermediate and long-acting variants ensure baseline glucose regulation. Oral medications represent a growing segment, driven by patient preference for non-invasive options. Metformin dominates this space due to its proven safety and effectiveness during pregnancy. Sulfonylureas, though effective, see limited use due to potential neonatal risks, making them a secondary option in clinical protocols.

For instance, Sanofi’s rapid-acting insulin analog, Apidra®, was documented in a multi-center study involving pregnant women with gestational diabetes, demonstrating a 29% reduction in postprandial blood sugar excursions compared to regular human insulin.

By Diagnosis

Diagnosis is bifurcated into the Glucose Challenge Test (GCT) and the Oral Glucose Tolerance Test (OGTT). OGTT leads in market share, favored for its accuracy in confirming gestational diabetes following abnormal GCT results. It is a widely adopted standard in prenatal screening protocols worldwide. GCT serves as an initial screening tool, especially in primary healthcare environments where rapid triage is required. Both tests remain integral in clinical pathways, supporting timely diagnosis and intervention across healthcare systems.

For instance, The Siemens ADVIA Chemistry Glucose Hexokinase analytical system is FDA 510(k) cleared for quantitative glucose testing in human serum and plasma. Its precision and throughput have led to widespread adoption in clinical laboratories, supporting large-scale screening protocols such as OGTT (oral glucose tolerance test) for gestational diabetes.

By End-user

Hospitals dominate the end-user segment due to their capacity for comprehensive maternal care, including diagnostics, inpatient treatment, and emergency support. Clinics rank next, offering accessible, routine screening services. Home care settings are expanding with the adoption of digital health tools for remote glucose monitoring. Diagnostic centers support standalone testing, catering to outpatients. Others, including maternity centers and telehealth platforms, play a supplementary role, reflecting the market’s gradual shift toward decentralized and tech-enabled care.

Segmentation:

By Treatment Segment

Insulin Therapy
Rapid-Acting Insulin
Short-Acting Insulin
Intermediate-Acting Insulin
Long-Acting Insulin
Oral Medications
Metformin
Sulfonylureas

By Diagnosis Segment

Glucose Challenge Test (GCT)
Oral Glucose Tolerance Test (OGTT)

By End-user Segment

Hospitals
Clinics
Home Care Settings
Diagnostic Centers
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

Regional Analysis:

North America

The North America Gestational Diabetes Market size was valued at USD 2,466.62 million in 2018 to USD 3,349.04 million in 2024 and is anticipated to reach USD 6,643.53 million by 2032, at a CAGR of 9.0% during the forecast period. It accounts for the largest regional share of approximately 35.3% in 2024. The region leads due to its robust healthcare infrastructure, high awareness, and consistent implementation of screening guidelines. It benefits from early diagnosis protocols and wide availability of treatment options, including advanced insulin therapies and digital monitoring tools. The U.S. drives regional dominance with substantial investment in maternal healthcare and high obesity prevalence. Canada supports growth with universal health coverage and integrated prenatal care. Market players focus on expanding wearable glucose devices and telehealth support across the region. North America continues to attract innovation and partnerships in gestational diabetes care. It maintains strong reimbursement frameworks and clinical research participation, reinforcing leadership in the global market.

Europe

The Europe Gestational Diabetes Market size was valued at USD 1,845.14 million in 2018 to USD 2,439.58 million in 2024 and is anticipated to reach USD 4,582.39 million by 2032, at a CAGR of 8.3% during the forecast period. It holds a regional market share of approximately 25.8% in 2024. European countries actively implement standardized prenatal screening practices across national healthcare systems. Germany, France, and the UK represent key markets due to their advanced diagnostic and treatment infrastructure. Public health agencies support patient education and promote gestational health through digital campaigns. The region adopts insulin therapies and oral medications widely, supported by favorable reimbursement. It also supports collaborative research into early biomarkers and non-invasive diagnostic methods. Policy-driven digital health expansion enhances access to glucose monitoring solutions. Europe’s focus on maternal and child well-being continues to strengthen its role in global gestational diabetes care.

Asia Pacific

The Asia Pacific Gestational Diabetes Market size was valued at USD 1,660.49 million in 2018 to USD 2,385.34 million in 2024 and is anticipated to reach USD 5,236.17 million by 2032, at a CAGR of 10.4% during the forecast period. It commands a regional share of approximately 25.2% in 2024 and is the fastest-growing region. Rapid urbanization, dietary changes, and delayed pregnancies contribute to rising gestational diabetes prevalence. China and India are central to market expansion due to their large pregnant populations and improving healthcare access. Governments introduce maternal screening programs in both rural and urban areas. Medical device manufacturers invest in low-cost glucose monitors to cater to underserved regions. It reflects high growth potential driven by public-private partnerships in prenatal diagnostics. Japan and South Korea adopt advanced insulin delivery and digital tracking solutions. Asia Pacific emerges as a strategic focus for global market participants targeting scalability and outreach.

Latin America

The Latin America Gestational Diabetes Market size was valued at USD 468.52 million in 2018 to USD 638.28 million in 2024 and is anticipated to reach USD 1,182.89 million by 2032, at a CAGR of 8.1% during the forecast period. It represents approximately 6.7% of the global market share in 2024. Brazil and Mexico lead the region with growing investments in maternal health infrastructure. Healthcare access in urban centers supports diagnosis and treatment availability, while rural areas remain underserved. National programs begin integrating gestational diabetes testing into routine prenatal care. Market growth is driven by awareness campaigns, improving insurance coverage, and mobile screening units. Pharmaceutical companies introduce affordable insulin and oral medication options to expand access. It sees increasing collaboration with NGOs and international health organizations. Clinics and diagnostic labs expand offerings to cover gestational diabetes detection. Latin America holds long-term potential with continued investment in public health systems.

Middle East

The Middle East Gestational Diabetes Market size was valued at USD 310.05 million in 2018 to USD 403.42 million in 2024 and is anticipated to reach USD 735.76 million by 2032, at a CAGR of 7.9% during the forecast period. It contributes around 4.3% to the global market in 2024. Countries such as Saudi Arabia, UAE, and Israel lead in adopting early detection protocols and insulin therapies. Rising rates of obesity and maternal age fuel demand for gestational diabetes care. Private sector hospitals and specialty clinics offer comprehensive diagnostic and treatment services. It benefits from national health reforms and digital health strategies that promote monitoring and teleconsultation. Government-backed maternal wellness programs encourage early testing. The region focuses on integrating AI-based screening tools for risk prediction. Market players explore partnerships to introduce cost-effective solutions. The Middle East sees steady market growth supported by healthcare modernization efforts.

Africa

The Africa Gestational Diabetes Market size was valued at USD 139.18 million in 2018 to USD 255.77 million in 2024 and is anticipated to reach USD 434.04 million by 2032, at a CAGR of 6.4% during the forecast period. It accounts for the smallest regional share at approximately 2.7% in 2024. Limited awareness and underdiagnosis continue to challenge the market. Urban centers in South Africa, Egypt, and Nigeria offer prenatal services that include gestational diabetes testing. Rural areas face access barriers due to resource constraints and insufficient healthcare personnel. NGOs and international organizations implement mobile health projects to improve outreach. Diagnostic manufacturers introduce portable kits tailored for low-infrastructure environments. It shows potential with ongoing maternal health investments and telemedicine expansion. Public-private collaborations work to train community health workers. Africa’s market development depends on scalable, low-cost solutions and greater awareness initiatives.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis:

Novo Nordisk A/S
Eli Lilly and Company
Sanofi S.A.
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd
Abbott Laboratories
AstraZeneca plc
Boehringer Ingelheim GmbH
Johnson & Johnson
Medtronic plc
Dexcom, Inc.
Biocon Limited
Bristol-Myers Squibb
Bayer AG
GlaxoSmithKline plc
Roche Diabetes Care
LifeScan Inc.
Ascensia Diabetes Care
Nipro Diagnostics
Peptron Inc.

Competitive Analysis:

The Global Gestational Diabetes Market features a moderately consolidated landscape dominated by multinational pharmaceutical and medical device companies. Key players include Novo Nordisk, Eli Lilly, Sanofi, Abbott, and Roche, all of which maintain strong portfolios in insulin therapies, glucose monitoring, and diagnostics. These companies invest in research to develop more effective treatments, personalized care models, and digital platforms. Mid-tier firms and regional players contribute by offering cost-effective solutions in emerging markets. Strategic alliances, product innovation, and geographic expansion remain central to gaining competitive advantage. Companies focus on integrating telehealth and AI to enhance patient engagement and clinical outcomes. Market participants aim to address growing demand through scalable, accessible treatment models.

Recent Developments:

In July 2025, Merck & Co., Inc. announced positive topline Phase 3 results for its investigational oral PCSK9 inhibitor, enlicitide, in treating adults with hyperlipidemia. This cardiovascular candidate showed clinically meaningful LDL cholesterol reductions, with regulatory filings planned following trial completion.
In June 2025, Sanofi S.A. announced the acquisition of Blueprint Medicines, expanding Sanofi’s rare immunology disease portfolio and adding the only approved therapy for advanced and indolent systemic mastocytosis to its pipeline. The deal was completed by July 18, 2025, accelerating growth in their immunology and allergy portfolio.
In July 2025, Merck & Co., Inc. announced positive topline Phase 3 results for its investigational oral PCSK9 inhibitor, enlicitide, in treating adults with hyperlipidemia. This cardiovascular candidate showed clinically meaningful LDL cholesterol reductions, with regulatory filings planned following trial completion.
In March 2025, F. Hoffmann-La Roche Ltd. entered an exclusive collaboration and licensing agreement with Zealand Pharma to co-develop petrelintide, an amylin analog for obesity and metabolic diseases. This move strengthens Roche’s metabolic disease pipeline by combining petrelintide with Roche’s own incretin assets.

Market Concentration & Characteristics:

The Global Gestational Diabetes Market demonstrates moderate-to-high concentration, with top companies controlling significant shares through diversified product lines and global reach. It is characterized by strong innovation, with companies advancing insulin analogs, oral medications, and smart monitoring tools. Market dynamics are shaped by regulatory frameworks, clinical guidelines, and rising demand in emerging regions. Strategic partnerships and product launches drive competitive positioning. It remains highly responsive to technological shifts and demographic trends influencing maternal healthcare.

Report Coverage:

The research report offers an in-depth analysis based on treatment, diagnosis, and end-user segments. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

Demand for early diagnostic tools will increase as healthcare systems prioritize maternal and fetal outcomes.
Adoption of continuous glucose monitoring and digital health platforms will accelerate across all income regions.
Insulin analogs and combination therapies will see strong growth due to evolving treatment protocols.
Emerging economies in Asia Pacific and Latin America will offer high-growth opportunities through public health investments.
Oral antidiabetic medications like metformin will gain popularity for their convenience and cost-effectiveness.
Government policies promoting universal prenatal screening will expand diagnosis rates globally.
Integration of AI and predictive analytics will support risk stratification and personalized interventions.
Home-based care and remote monitoring will become central to managing gestational diabetes efficiently.
Strategic collaborations between pharmaceutical and diagnostic companies will drive innovation and access.
Increasing focus on patient education and lifestyle modifications will strengthen long-term disease management.

CHAPTER NO. 1 : GENESIS OF THE MARKET

1.1 Market Prelude – Introduction & Scope

1.2 The Big Picture – Objectives & Vision

1.3 Strategic Edge – Unique Value Proposition

1.4 Stakeholder Compass – Key Beneficiaries

CHAPTER NO. 2 : EXECUTIVE LENS

2.1 Pulse of the Industry – Market Snapshot

2.2 Growth Arc – Revenue Projections (USD Million)

2.3. Premium Insights – Based on Primary Interviews

CHAPTER NO. 3 : GESTATIONAL DIABETES MARKET FORCES & INDUSTRY PULSE

3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown

3.6 Price Trend Analysis

3.6.1 Regional Price Trend
3.6.2 Price Trend by product

CHAPTER NO. 4 : KEY INVESTMENT EPICENTER

4.1 Regional Goldmines – High-Growth Geographies

4.2 Treatment Frontiers – Lucrative Treatment Categories

4.3 Diagnosis Sweet Spots – Emerging Demand Segments

CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING

5.1 Momentum Metrics – Forecast & Growth Curves

5.2 Regional Revenue Footprint – Market Share Insights

5.3 Segmental Wealth Flow – Treatment & Diagnosis Revenue

CHAPTER NO. 6 : TRADE & COMMERCE ANALYSIS

6.1. Import Analysis by Region

6.1.1. Global Gestational Diabetes Market Import Revenue By Region

6.2. Export Analysis by Region

6.2.1. Global Gestational Diabetes Market Export Revenue By Region

CHAPTER NO. 7 : COMPETITION ANALYSIS

7.1. Company Market Share Analysis

7.1.1. Global Gestational Diabetes Market: Company Market Share

7.2. Global Gestational Diabetes Market Company Revenue Market Share

7.3. Strategic Developments

7.3.1. Acquisitions & Mergers

7.3.2. New Treatment Launch

7.3.3. Regional Expansion

7.4. Competitive Dashboard

7.5. Company Assessment Metrics, 2024

CHAPTER NO. 8 : GESTATIONAL DIABETES MARKET – BY TREATMENT SEGMENT ANALYSIS

8.1. Gestational Diabetes Market Overview by Treatment Segment

8.1.1. Gestational Diabetes Market Revenue Share By Treatment

8.2. Insulin Therapy

8.3. Rapid-Acting Insulin

8.4. Short-Acting Insulin

8.5. Intermediate-Acting Insulin

8.6. Long-Acting Insulin

8.7. Oral Medications

8.8. Metformin

8.9. Sulfonylureas

CHAPTER NO. 9 : GESTATIONAL DIABETES MARKET – BY DIAGNOSIS SEGMENT ANALYSIS

9.1. Gestational Diabetes Market Overview by Diagnosis Segment

9.1.1. Gestational Diabetes Market Revenue Share By Diagnosis

9.2. Glucose Challenge Test (GCT)

9.3. Oral Glucose Tolerance Test (OGTT)

CHAPTER NO. 10 : GESTATIONAL DIABETES MARKET – BY END-USER SEGMENT ANALYSIS

10.1. Gestational Diabetes Market Overview by End-user Segment

10.1.1. Gestational Diabetes Market Revenue Share By End-user

10.2. Hospitals

10.3. Clinics

10.4. Home Care Settings

10.5. Diagnostic Centers

10.6. Others

CHAPTER NO. 11 : GESTATIONAL DIABETES MARKET – REGIONAL ANALYSIS

11.1. Gestational Diabetes Market Overview by Region Segment

11.1.1. Global Gestational Diabetes Market Revenue Share By Region

11.1.3. Regions

11.1.4. Global Gestational Diabetes Market Revenue By Region

.1.6. Treatment

11.1.7. Global Gestational Diabetes Market Revenue By Treatment

11.1.9. Diagnosis

11.1.10. Global Gestational Diabetes Market Revenue By Diagnosis

11.1.12. End-user

11.1.13. Global Gestational Diabetes Market Revenue By End-user

CHAPTER NO. 12 : NORTH AMERICA GESTATIONAL DIABETES MARKET – COUNTRY ANALYSIS

12.1. North America Gestational Diabetes Market Overview by Country Segment

12.1.1. North America Gestational Diabetes Market Revenue Share By Region

12.2. North America

12.2.1. North America Gestational Diabetes Market Revenue By Country

12.2.2. Treatment

12.2.3. North America Gestational Diabetes Market Revenue By Treatment

12.2.4. Diagnosis

12.2.5. North America Gestational Diabetes Market Revenue By Diagnosis

2.2.6. End-user

12.2.7. North America Gestational Diabetes Market Revenue By End-user

2.3. U.S.

12.4. Canada

12.5. Mexico

CHAPTER NO. 13 : EUROPE GESTATIONAL DIABETES MARKET – COUNTRY ANALYSIS

13.1. Europe Gestational Diabetes Market Overview by Country Segment

13.1.1. Europe Gestational Diabetes Market Revenue Share By Region

13.2. Europe

13.2.1. Europe Gestational Diabetes Market Revenue By Country

13.2.2. Treatment

13.2.3. Europe Gestational Diabetes Market Revenue By Treatment

13.2.4. Diagnosis

13.2.5. Europe Gestational Diabetes Market Revenue By Diagnosis

13.2.6. End-user

13.2.7. Europe Gestational Diabetes Market Revenue By End-user

13.3. UK

13.4. France

13.5. Germany

13.6. Italy

13.7. Spain

13.8. Russia

13.9. Rest of Europe

CHAPTER NO. 14 : ASIA PACIFIC GESTATIONAL DIABETES MARKET – COUNTRY ANALYSIS

14.1. Asia Pacific Gestational Diabetes Market Overview by Country Segment

14.1.1. Asia Pacific Gestational Diabetes Market Revenue Share By Region

14.2. Asia Pacific

14.2.1. Asia Pacific Gestational Diabetes Market Revenue By Country

14.2.2. Treatment

14.2.3. Asia Pacific Gestational Diabetes Market Revenue By Treatment

14.2.4. Diagnosis

14.2.5. Asia Pacific Gestational Diabetes Market Revenue By Diagnosis

14.2.5. End-user

14.2.7. Asia Pacific Gestational Diabetes Market Revenue By End-user

14.3. China

14.4. Japan

14.5. South Korea

14.6. India

14.7. Australia

14.8. Southeast Asia

14.9. Rest of Asia Pacific

CHAPTER NO. 15 : LATIN AMERICA GESTATIONAL DIABETES MARKET – COUNTRY ANALYSIS

15.1. Latin America Gestational Diabetes Market Overview by Country Segment

15.1.1. Latin America Gestational Diabetes Market Revenue Share By Region

15.2. Latin America

15.2.1. Latin America Gestational Diabetes Market Revenue By Country

15.2.2. Treatment

15.2.3. Latin America Gestational Diabetes Market Revenue By Treatment

15.2.4. Diagnosis

15.2.5. Latin America Gestational Diabetes Market Revenue By Diagnosis

15.2.6. End-user

15.2.7. Latin America Gestational Diabetes Market Revenue By End-user

15.3. Brazil

15.4. Argentina

15.5. Rest of Latin America

CHAPTER NO. 16 : MIDDLE EAST GESTATIONAL DIABETES MARKET – COUNTRY ANALYSIS

16.1. Middle East Gestational Diabetes Market Overview by Country Segment

16.1.1. Middle East Gestational Diabetes Market Revenue Share By Region

16.2. Middle East

16.2.1. Middle East Gestational Diabetes Market Revenue By Country

16.2.2. Treatment

16.2.3. Middle East Gestational Diabetes Market Revenue By Treatment

16.2.4. Diagnosis

16.2.5. Middle East Gestational Diabetes Market Revenue By Diagnosis

16.2.6. End-user

16.2.7. Middle East Gestational Diabetes Market Revenue By End-user

16.3. GCC Countries

16.4. Israel

16.5. Turkey

16.6. Rest of Middle East

CHAPTER NO. 17 : AFRICA GESTATIONAL DIABETES MARKET – COUNTRY ANALYSIS

17.1. Africa Gestational Diabetes Market Overview by Country Segment

17.1.1. Africa Gestational Diabetes Market Revenue Share By Region

17.2. Africa

17.2.1. Africa Gestational Diabetes Market Revenue By Country

17.2.2. Treatment

17.2.3. Africa Gestational Diabetes Market Revenue By Treatment

17.2.4. Diagnosis

17.2.5. Africa Gestational Diabetes Market Revenue By Diagnosis

17.2.6. End-user

17.2.7. Africa Gestational Diabetes Market Revenue By End-user

17.3. South Africa

17.4. Egypt

17.5. Rest of Africa

CHAPTER NO. 18 : COMPANY PROFILES

18.1. Novo Nordisk A/S

18.1.1. Company Overview

18.1.2. Treatment Portfolio

18.1.3. Financial Overview

18.1.4. Recent Developments

18.1.5. Growth Strategy

18.1.6. SWOT Analysis

18.2. Eli Lilly and Company

18.3. Sanofi S.A.

18.4. Merck & Co., Inc.

18.5. F. Hoffmann‑La Roche Ltd

18.6. Abbott Laboratories

18.7. AstraZeneca plc

18.8. Boehringer Ingelheim GmbH

18.9. Johnson & Johnson

18.10. Medtronic plc

18.11. Dexcom, Inc.

18.12. Biocon Limited

18.13. Bristol‑Myers Squibb

18.14. Bayer AG

18.15. GlaxoSmithKline plc

18.16. Roche Diabetes Care

18.17. LifeScan Inc.

18.18. Ascensia Diabetes Care

18.19. Nipro Diagnostics

18.20. Peptron Inc.

Frequently Asked Questions

What is the current size of the Global Gestational Diabetes Market?

The market was valued at USD 6,890.00 million in 2018 and reached USD 9,471.43 million in 2024. It is projected to grow significantly and reach USD 18,814.79 million by 2032, driven by increasing prevalence and healthcare advancements.

What are the key segments within the Global Gestational Diabetes Market?

The market is segmented by treatment (insulin therapy, oral medications), diagnosis (OGTT, GCT), and end users (hospitals, clinics, home care, diagnostic centers). These segments cater to different stages of care and delivery models.

What are some challenges faced by the Global Gestational Diabetes Market?

Challenges include limited access to diagnostic tools in rural areas, treatment non-compliance, and insufficient awareness in low-income regions. Behavioral barriers and infrastructure limitations also hinder full market potential.

Who are the major players in the Global Gestational Diabetes Market?

Leading companies include Novo Nordisk, Eli Lilly, Sanofi, Abbott Laboratories, and Roche. These firms focus on insulin therapies, diagnostics, and digital health to improve treatment outcomes and expand market reach.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Reviewed By
Gunakesh Parmar

Research Consultant

With over 15 years of dedicated experience in market research since 2009, specializes in delivering actionable insights from data.

View Profile

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$12699

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –